

Proto Labs Inc  
Form 10-Q  
November 05, 2013  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2013**

**or**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 001-35435**

**Proto Labs, Inc.**

**(Exact name of registrant as specified in its charter)**

<b>Minnesota</b> <b>(State or other jurisdiction of</b>	<b>41-1939628</b> <b>(I.R.S. Employer</b>
<b>incorporation or organization)</b>	<b>Identification No.)</b>
<b>5540 Pioneer Creek Drive</b> <b>Maple Plain, Minnesota</b> <b>(Address of principal executive offices)</b>	<b>55359</b> <b>(Zip Code)</b>
<b>(763) 479-3680</b> <b>(Registrant's telephone number, including area code)</b>	

**Not Applicable**

**(Former name, former address and former fiscal year, if changed since last report)**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer <input type="checkbox"/>	Accelerated filer <input type="checkbox"/>
Non-accelerated filer <input checked="" type="checkbox"/> (Do not check if a smaller reporting company)	Smaller reporting company <input type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 25,461,373 shares of Common Stock, par value \$0.001 per share, were outstanding at October 31, 2013.



**Table of Contents**

**Proto Labs, Inc.**

**TABLE OF CONTENTS**

<b>Item</b>	<b>Description</b>	<b>Page</b>
<b><u>PART I</u></b>		
1.	<u>Financial Statements</u>	3
2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	13
3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	22
4.	<u>Controls and Procedures</u>	23
<b><u>PART II</u></b>		
1.	<u>Legal Proceedings</u>	24
1A.	<u>Risk Factors</u>	24
6.	<u>Exhibits</u>	24

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****Proto Labs, Inc.****Consolidated Balance Sheets****(In thousands, except share and per share amounts)**

	<b>September 30, 2013 (Unaudited)</b>	<b>December 31, 2012</b>
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 39,382	\$ 36,759
Short-term marketable securities	33,647	25,137
Accounts receivable, net of allowance for doubtful accounts of \$195 and \$154 as of September 30, 2013 and December 31, 2012, respectively	18,016	15,791
Inventory	4,966	4,619
Prepaid expenses and other current assets	3,663	5,364
Income taxes receivable	3,970	1,877
Deferred tax assets	669	609
Total current assets	104,313	90,156
Property and equipment, net	52,378	45,316
Long-term marketable securities	59,441	36,965
Other assets	247	285
Total assets	\$ 216,379	\$ 172,722
<b>Liabilities and shareholders equity</b>		
Current liabilities		
Accounts payable	\$ 6,340	\$ 4,758
Accrued compensation	6,848	5,995
Accrued liabilities and other	1,149	513
Current portion of long-term debt obligations	195	273
Total current liabilities	14,532	11,539
Long-term deferred tax liabilities	3,345	3,346
Long-term debt obligations	206	356
Other long-term liabilities	699	782
Total liabilities	18,782	16,023
Shareholders equity		

Edgar Filing: Proto Labs Inc - Form 10-Q

Preferred stock, \$0.001 par value, authorized 10,000,000 shares; issued and outstanding 0 shares as of September 30, 2013 and December 31, 2012, respectively		
Common stock, \$0.001 par value, authorized 150,000,000 shares; issued and outstanding 25,445,177 and 24,803,640 shares as of September 30, 2013 and December 31, 2012, respectively	26	25
Additional paid-in capital	162,458	147,032
Retained earnings	36,340	10,570
Accumulated other comprehensive income (loss)	(1,227)	(928)
Total shareholders equity	197,597	156,699
Total liabilities and shareholders equity	\$ 216,379	\$ 172,722

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****Proto Labs, Inc.****Consolidated Statements of Comprehensive Income****(In thousands, except share and per share amounts)****(Unaudited)**

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2013</b>	<b>2012</b>	<b>2013</b>	<b>2012</b>
<b>Statements of Operations:</b>				
Revenue	\$ 42,008	\$ 32,454	\$ 119,070	\$ 92,375
Cost of revenue	16,053	12,760	44,983	37,242
Gross profit	25,955	19,694	74,087	55,133
Operating expenses				
Marketing and sales	5,409	4,442	16,222	13,440
Research and development	3,026	2,561	8,405	6,622
General and administrative	4,118	3,118	12,035	10,394
Total operating expenses	12,553	10,121	36,662	30,456
Income from operations	13,402	9,573	37,425	24,677
Other income (expense), net	31	314	149	(90)
Income before income taxes	13,433	9,887	37,574	24,587
Provision for income taxes	4,561	3,185	11,804	7,957
Net income	\$ 8,872	\$ 6,702	\$ 25,770	\$ 16,630
<b>Net income per share:</b>				
Basic	\$ 0.35	\$ 0.28	\$ 1.03	\$ 0.72
Diluted	\$ 0.34	\$ 0.26	\$ 1.00	\$ 0.68
Shares used to compute net income per share:				
Basic	25,384,940	24,052,409	25,121,941	22,975,950
Diluted	26,002,240	25,312,643	25,794,950	24,356,785
<b>Other Comprehensive Income (net of tax)</b>				
Comprehensive income	\$ 9,678	\$ 6,756	\$ 25,471	\$ 16,827

The accompanying notes are an integral part of these consolidated financial statements.





**Table of Contents****Proto Labs, Inc.****Consolidated Statements of Cash Flows****(In thousands)****(Unaudited)**

	<b>Nine Months Ended September 30,</b>	
	<b>2013</b>	<b>2012</b>
<b>Operating activities</b>		
Net income	\$ 25,770	\$ 16,630
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	5,528	4,380
Stock-based compensation expense	2,595	2,362
Deferred taxes	(61)	
Excess tax benefit from stock-based compensation	(8,198)	(2,635)
Loss on disposal of property and equipment	111	
Amortization of held-to-maturity securities	1,007	173
Changes in operating assets and liabilities:		
Accounts receivable	(2,242)	(3,777)
Inventories	(380)	(513)
Prepaid expenses and other	1,545	(256)
Income taxes	6,099	2,350
Accounts payable	1,564	(312)
Accrued liabilities and other	1,562	1,032
Net cash provided by operating activities	34,900	19,434
<b>Investing activities</b>		
Purchases of property and equipment	(12,976)	(14,435)
Purchases of marketable securities	(82,657)	(61,568)
Proceeds from maturities of marketable securities	50,663	10,290
Net cash used in investing activities	(44,970)	(65,713)
<b>Financing activities</b>		
Proceeds from initial public offering, net of offering costs		71,530
Payments on debt	(211)	(289)
Proceeds from exercises of warrants and stock options	4,635	728
Excess tax benefit from stock-based compensation	8,198	2,635
Net cash provided by financing activities	12,622	74,604
Effect of exchange rate changes on cash and cash equivalents	71	(170)

<b>Net increase in cash and cash equivalents</b>	2,623	28,155
<b>Cash and cash equivalents, beginning of period</b>	36,759	8,135
<b>Cash and cash equivalents, end of period</b>	\$ 39,382	\$ 36,290

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

**Proto Labs, Inc.**

**Notes to Consolidated Financial Statements**

**(Unaudited)**

**Note 1 Basis of Presentation**

The unaudited interim Consolidated Financial Statements of Proto Labs, Inc. (Proto Labs, the Company, we, us or our) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. These statements are unaudited but, in the opinion of management, reflect all adjustments necessary for a fair presentation of the Company's statement of financial position, results of operations and cash flows for the periods presented. Except as otherwise disclosed herein, these adjustments consist of normal, recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission (SEC) on March 22, 2013.

The accompanying Consolidated Balance Sheet as of December 31, 2012 was derived from the audited Consolidated Financial Statements but does not include all disclosures required by U.S. GAAP for a full set of financial statements. This Form 10-Q should be read in conjunction with the Company's Consolidated Financial Statements and Notes included in the Annual Report on Form 10-K filed on March 22, 2013 as referenced above.

Certain reclassifications have been made to the Consolidated Statement of Cash Flows for the nine month period ending September 30, 2012 to conform to the presentation used in the September 30, 2013 Consolidated Statement of Cash Flows. The reclassifications had no effect on the increase in cash and cash equivalents as previously reported.

**Note 2 Recent Accounting Pronouncements**

In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02, *Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income* (ASU 2013-02). This accounting update generally requires entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, the accounting update requires entities to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. The amendment applies to public and nonpublic companies and is to be applied prospectively. For public entities, the amendment is effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. The Company adopted this accounting guidance effective January 1, 2013. The adoption of ASU 2013-02 did not have a material impact on the Company's financial statements.

**Note 3 Net Income per Common Share**

Basic net income per share is computed based on the weighted-average number of common shares outstanding. Diluted net income per share is computed based on the weighted-average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include stock options granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

**Table of Contents****Proto Labs, Inc.****Notes to Consolidated Financial Statements****(Unaudited)**

The table below sets forth the computation of basic and diluted net income per share:

(in thousands, except share and per share amounts)	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2013</b>	<b>2012</b>	<b>2013</b>	<b>2012</b>
Net income	\$ 8,872	\$ 6,702	\$ 25,770	\$ 16,630
Basic weighted-average shares outstanding:	25,384,940	24,052,409	25,121,941	22,975,950
Effect of dilutive securities:				
Employee stock options, warrants and other	617,300	1,260,234	673,009	1,380,835
Diluted weighted-average shares outstanding:	26,002,240	25,312,643	25,794,950	24,356,785
Net income per share:				
Basic	\$ 0.35	\$ 0.28	\$ 1.03	\$ 0.72
Diluted	\$ 0.34	\$ 0.26	\$ 1.00	\$ 0.68

**Note 4 Fair Value Measurements**

Accounting Standards Codification (ASC) 820, *Fair Value Measurement* (ASC 820), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:

*Level 1* Quoted prices in active markets for identical assets or liabilities.

*Level 2* Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

*Level 3* Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Edgar Filing: Proto Labs Inc - Form 10-Q

The Company's cash consists of bank deposits. The Company's cash equivalents measured at fair value consist of money market mutual funds. The Company determines the fair value of these investments using Level 1 inputs.

A summary of financial assets as of September 30, 2013 and December 31, 2012 measured at fair value on a recurring basis follows:

(in thousands)	September 30, 2013			December 31, 2012		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
<b>Financial Assets:</b>						
Cash and cash equivalents						
Money market mutual fund	\$ 14,804	\$	\$	\$ 16,164	\$	\$
Total	\$ 14,804	\$	\$	\$ 16,164	\$	\$

**Table of Contents****Proto Labs, Inc.****Notes to Consolidated Financial Statements****(Unaudited)****Note 5 Marketable Securities**

The Company invests in short-term and long-term agency, municipal, corporate, commercial paper and other debt securities. The securities are categorized as held-to-maturity and are recorded at amortized cost. Categorization as held-to-maturity is based on the Company's ability and intent to hold these securities to maturity. Information regarding the Company's short-term and long-term marketable securities as of September 30, 2013 and December 31, 2012 is as follows:

(in thousands)	September 30, 2013			Fair Value
	Amortized Cost	Unrealized Gains	Unrealized Losses	
U.S. government agency securities	\$ 21,588	\$ 9	\$ (11)	\$ 21,586
Corporate debt securities	27,028	22	(39)	27,011
Commercial paper	1,999			1,999
U.S. municipal securities	38,768	25	(34)	38,759
Certificates of deposit/time deposits	3,705	6	(9)	3,702
Total marketable securities	\$ 93,088	\$ 62	\$ (93)	\$ 93,057

(in thousands)	December 31, 2012			Fair Value
	Amortized Cost	Unrealized Gains	Unrealized Losses	
U.S. government agency securities	\$ 23,011	\$ 2	\$ (4)	\$ 23,009
Corporate debt securities	14,675	18	(14)	14,679
Commercial paper	1,500			1,500
U.S. municipal securities	17,971	3	(12)	17,962
Certificates of deposit/time deposits	4,945	3	(1)	4,947
Total marketable securities	\$ 62,102	\$ 26	\$ (31)	\$ 62,097

Fair values for the U.S. government agency and corporate debt securities are primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, certificates of deposit and commercial paper are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).

The Company tests for other than temporary losses on a quarterly basis and has considered the unrealized losses indicated above to be temporary in nature. The Company intends to hold the investments to maturity and recover the

full principal.

Classification of marketable securities as current or non-current is based upon the security's maturity date as of the date of these financial statements.

The September 30, 2013 balance of held-to-maturity debt securities by contractual maturity is shown in the following table at amortized cost. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.



**Table of Contents****Proto Labs, Inc.****Notes to Consolidated Financial Statements****(Unaudited)**

(in thousands)	<b>September 30, 2013</b>
Due in one year or less	\$ 33,647
Due after one year through five years	59,441
<b>Total marketable securities</b>	<b>\$ 93,088</b>

**Note 6 Inventory**

Inventory consists primarily of raw materials, which are recorded at the lower of cost or market using the average-cost method, which approximates first-in, first-out (FIFO) cost. The Company periodically reviews its inventory for slow-moving, damaged and discontinued items and provides allowances to reduce such items identified to their recoverable amounts.

The Company's inventory consists of the following:

(in thousands)	<b>September 30, 2013</b>	<b>December 31, 2012</b>
Raw materials	\$ 4,795	\$ 4,174
Work in process	282	530
<b>Total inventory</b>	<b>5,077</b>	<b>4,704</b>
Allowance for obsolescence	(111)	(85)
<b>Inventory, net of allowance</b>	<b>\$ 4,966</b>	<b>\$ 4,619</b>

**Note 7 Stock-Based Compensation**

Under the 2012 Long-Term Incentive Plan (2012 Plan), as discussed in the 2012 Annual Report on Form 10-K, the Company has the ability to grant stock options, stock appreciation rights (SARs), restricted stock, stock units, other stock-based awards and cash incentive awards. Awards under the 2012 Plan will have a maximum term of ten years from the date of grant. The compensation committee may provide that the vesting or payment of any award will be subject to the attainment of specified performance measures in addition to the satisfaction of any continued service requirements and the compensation committee will determine whether such measures have been achieved. The per share exercise price of stock options and SARs granted under the 2012 Plan generally may not be less than the fair market value of a share of our common stock on the date of the grant.

**Employee Stock Purchase Plan**

The Company's 2012 Employee Stock Purchase Plan (ESPP), as discussed in the 2012 Annual Report on Form 10-K, allows eligible employees to purchase shares of the Company's common stock at a discount through payroll deductions of up to 15 percent of their eligible compensation, subject to plan limitations. The ESPP provides for six-month offering periods ending May 15 and November 15, respectively. At the end of each offering period, employees are able to purchase shares at 85 percent of the lower of the fair market value of the Company's common stock on the first trading day of the offering period or on the last trading day of the offering period.

**Table of Contents****Proto Labs, Inc.****Notes to Consolidated Financial Statements****(Unaudited)****Stock-Based Compensation Expense**

Stock-based compensation expense was \$0.9 million and \$0.7 million for the three months ended September 30, 2013 and 2012, and \$2.6 million and \$2.4 million for the nine months ended September 30, 2013 and 2012, respectively.

**Stock Options**

A summary of stock option activity for the nine months ended September 30, 2013 is as follows:

	<b>Stock Options</b>	<b>Weighted- Average Exercise Price</b>
Options outstanding at December 31, 2012	1,691,357	\$ 11.11
Granted	187,615	49.69
Exercised	(607,372)	6.81
Forfeited	(39,945)	23.48
Options outstanding at September 30, 2013	1,231,655	\$ 18.71
Exercisable at September 30, 2013	439,374	\$ 10.61

The outstanding options generally have a term of ten years. For employees, options granted become exercisable ratably over the vesting period, which is generally a five-year period beginning on the first anniversary of the grant date, subject to the employee's continuing service to the Company. For directors, options generally become exercisable in full on the first anniversary of the grant date.

The weighted-average grant date fair value of options that were granted during the nine months ended September 30, 2013 was \$25.86.

The following table provides the assumptions used in the Black-Scholes pricing model valuation of options:

	<b>Nine Months Ended September 30,</b>			
	<b>2013</b>		<b>2012</b>	
Risk-free interest rate	1.03	1.98%	0.95	1.16%
Expected life (years)	5.50	6.50	5.50	6.50

Expected volatility	49.36	53.54%	53.00	53.14%
Expected dividend yield		0%		0%

As of September 30, 2013, there was \$7.3 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.7 years.

**Employee Stock Purchase Plan**

The following table presents the assumptions used to estimate the fair value of the ESPP during the nine months ended September 30, 2013 and 2012, respectively:

Table of Contents

## Proto Labs, Inc.

## Notes to Consolidated Financial Statements

(Unaudited)

	Nine Months Ended September 30,			
	2013		2012	
Risk-free interest rate	0.11	0.13%		0.16%
Expected life (months)	6.00			8.50
Expected volatility	53.14	53.32%		53.00%
Expected dividend yield		0%		0%

**Note 8 Accumulated Other Comprehensive Income**

Other comprehensive income (loss) is comprised entirely of foreign currency translation adjustments. The following table presents the changes in accumulated other comprehensive income balances during the three and nine month periods ended September 30, 2013 and 2012, respectively:

(in thousands)	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
Foreign currency translation adjustment, net of tax				
Balance at beginning of period	\$ (2,033)	\$ (595)	\$ (928)	\$ (738)
Other comprehensive income before reclassifications	806	54	(299)	197
Amounts reclassified from accumulated other comprehensive income				
Net current-period other comprehensive income	806	54	(299)	197
Balance at end of period	\$ (1,227)	\$ (541)	\$ (1,227)	\$ (541)

**Note 9 Income Taxes**

The Company is subject to income tax in multiple jurisdictions and the use of estimates is required to determine the provision for income taxes. For the three months ended September 30, 2013 and 2012 the Company recorded an income tax provision of \$4.6 million and \$3.2 million, respectively. For the nine months ended September 30, 2013 and 2012 the Company recorded an income tax provision of \$11.8 million and \$8.0 million, respectively. The income tax provision is based on the estimated annual effective tax rate for the year applied to pre-tax income. The effective income tax rate for the three months ended September 30, 2013 was 34.0 percent compared with 32.2 percent in the same period of the prior year. The effective income tax rate for the nine months ended September 30, 2013 was 31.4 percent compared with 32.4 percent in the same period of the prior year.

The effective income tax rate for the three months ended September 30, 2013 differs from the U.S. federal statutory rate of 35 percent primarily due to the components of income. The effective income tax rate for the nine months ended September 30, 2013 differs from the U.S. federal statutory rate of 35 percent primarily due to the components of income, particularly as it relates to the federal research and development credit. On January 2, 2013, the American Taxpayer Relief Act of 2012 (the Act) was signed into law, extending the research and development credit for years 2012 and 2013. As the Act was enacted during 2013, the federal portion of the 2012 research and development credit was recognized in the first quarter of 2013. The Company recorded a tax benefit of \$0.3 million for the 2012 federal research credit, which translated to an effective income tax rate reduction of 1.0 percent for the nine months ended September 30, 2013.

The Company has liabilities related to unrecognized tax benefits totaling \$0.4 million at September 30, 2013 and December 31, 2012. There were no material adjustments to the unrecorded tax benefits during the three or nine month periods ended September 30, 2013, and the Company does not anticipate that total unrecognized tax benefits will materially change in the next twelve months. The Company recognizes interest and penalties related to income tax matters in income tax expense, and reports the liability in current or long-term income taxes payable as appropriate.

Table of Contents

## Proto Labs, Inc.

## Notes to Consolidated Financial Statements

(Unaudited)

**Note 10 Revenue and Geographic Information**

The Company's revenue is derived from its Protomold injection molding and Firstcut computer numerical control (CNC) machining product lines. Total revenue by product line is as follows:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2013	2012	2013	2012
<b>Revenue:</b>				
Protomold	\$ 29,534	\$ 23,458	\$ 84,338	\$ 66,697
Firstcut	12,474	8,996	34,732	25,678
Total revenue	\$ 42,008	\$ 32,454	\$ 119,070	\$ 92,375

Revenue to external customers based on the billing location of the end user customer and long-lived assets by geographic region are as follows:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2013	2012	2013	2012
<b>Revenue:</b>				
United States	\$ 30,561	\$ 24,807	\$ 88,816	\$ 69,887
International	11,447	7,647	30,254	22,488
Total revenue	\$ 42,008	\$ 32,454	\$ 119,070	\$ 92,375

(in thousands)	September 30, 2013	December 31, 2012
<b>Long-lived assets:</b>		
United States	\$ 44,877	\$ 37,869
International	7,501	7,447

Edgar Filing: Proto Labs Inc - Form 10-Q

Total long-lived assets	\$	52,378	\$	45,316
-------------------------	----	--------	----	--------



---

**Table of Contents**

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2012.*

**Forward-Looking Statements**

Statements contained in this report regarding matters that are not historical or current facts are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms and comparable terminology, although not all forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other factors which may cause our results to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in Item 1A. Risk Factors of our Annual Report on Form 10-K as filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on our future results. We cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, we expressly disclaim any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

**Overview**

We are a leading online and technology-enabled manufacturer of quick-turn CNC-machined and injection-molded custom parts for prototyping and short-run production. We provide Real Parts, Really Fast to product developers worldwide, who are under increasing pressure to bring their finished products to market faster than their competition. We believe low-volume manufacturing has historically been an underserved market due to the inefficiencies inherent in the quotation, equipment set-up and non-recurring engineering processes required to produce custom parts. Our proprietary technology eliminates most of the time-consuming and expensive skilled labor conventionally required to quote and manufacture parts in low volumes, and our customers conduct nearly all of their business with us over the Internet. We target our services to the millions of product developers who use three-dimensional computer-aided design (3D CAD) software to design products across a diverse range of end-markets. Our primary manufacturing services currently include Firstcut, which is our CNC machining service, and Protomold, which is our injection molding service.

**Key Financial Measures and Trends**

***Revenue***

The Company's operations are comprised of three geographic business units in the United States, Europe and Japan. Revenue within each of our business units is derived from our Firstcut and Protomold services. Firstcut revenue consists of sales of CNC-machined custom parts. Protomold revenue consists of sales of custom injection molds and injection-molded parts. Our historical and current efforts to increase revenue have been directed at gaining new customers and selling to our existing customer base by increasing marketing and selling activities, offering additional services such as the introduction of our Firstcut service in 2007, expanding internationally such as the opening of our Japanese plant in 2009, improving the usability of our services such as our web-centric applications, and expanding the breadth and scope of our products such as by adding more sizes and materials to our offerings. During the three months ended September 30, 2013, we served approximately 7,300 unique product developers, an increase of 23%

over the same period in 2012. During the nine months ended September 30, 2013, we served approximately 13,400 unique product developers, an increase of 21% over the same period in 2012.

***Cost of Revenue, Gross Profit and Gross Margin***

Cost of revenue consists primarily of raw materials, equipment depreciation, employee salaries, benefits, stock-based compensation, bonuses and overhead allocations associated with the manufacturing process for molds and custom parts. We expect cost of revenue to increase in absolute dollars, but remain relatively constant as a percentage of total revenue.

We define gross profit as our revenue less our cost of revenue, and we define gross margin as gross profit expressed as a percentage of revenue. Our gross profit and gross margin are affected by many factors, including pricing, sales volume and manufacturing costs, the costs associated with increasing production capacity, the mix between domestic and foreign revenue sources and foreign exchange rates.

## **Table of Contents**

Our gross margins vary between geographic markets due primarily to the costs associated with starting new factories and our operating maturity in these markets. We believe that over time and with growth and maturity of our international business, gross margins will be generally consistent through all our markets.

### ***Operating Expenses***

Operating expenses consist of marketing and sales, research and development and general and administrative. Personnel-related costs are the most significant component of the marketing and sales, research and development and general and administrative expense categories.

Our recent growth in operating expenses is mainly due to higher headcounts to support our growth and expansion, and we expect that trend to continue. Our business strategy is to continue to be a leading online and technology-enabled manufacturer of quick-turn CNC machined and injection-molded custom parts for prototyping and short-run production. For us to achieve our goals, we anticipate continued substantial investments in technology and personnel, resulting in increased operating expenses.

*Marketing and sales.* Marketing and sales expense consists primarily of employee salaries, benefits, commissions, stock-based compensation, bonuses, marketing programs such as print and pay-per-click advertising, trade shows, direct mail and other related overhead. We expect sales and marketing expense to increase in the future as we increase the number of marketing and sales professionals and marketing programs targeted to increase our customer base.

*Research and development.* Research and development expense consists primarily of employee salaries, benefits, stock-based compensation, bonuses, depreciation on equipment, outside services and other related overhead. All of our research and development costs have been expensed as incurred. We expect research and development expense to increase in the future as we seek to enhance and expand our service offerings.

*General and administrative.* General and administrative expense consists primarily of employee salaries, benefits, stock-based compensation, bonuses, professional service fees related to accounting, tax and legal, and other related overhead. We expect general and administrative expense to increase on an absolute basis and as a percentage of revenue as we continue to grow and expand our operations and develop the infrastructure necessary to operate as a public company. These expenses will include increased audit and legal fees, costs of compliance with securities and other regulations, implementation costs for compliance with the provisions of the Sarbanes-Oxley Act, investor relations expense and higher insurance premiums.

### ***Other Income (Expense), net***

Other income (expense), net primarily consists of foreign currency-related gains and losses, interest income on cash balances and investments, and interest expense on borrowings. Our foreign currency-related gains and losses will vary depending upon movements in underlying exchange rates. Our interest income will vary each reporting period depending on our average cash balances during the period, composition of our marketable security portfolio and the current level of interest rates. Our interest expense will vary based on borrowings and interest rates.

### ***Provision for Income Taxes***

Provision for income taxes is comprised of federal, state, local and foreign taxes based on pre-tax income. We expect income taxes to increase as our taxable income increases and our effective tax rate to remain relatively constant.

## **Results of Operations**

## Edgar Filing: Proto Labs Inc - Form 10-Q

The following table sets forth a summary of our results of operations and the related changes for the periods indicated. The results below are not necessarily indicative of the results for future periods.

**Table of Contents**

	Three Months Ended September 30,				Change		Nine Months Ended September 30,				Change	
	2013		2012		\$	%	2013		2012		\$	%
Revenue (dollars in thousands)	\$ 42,008	100.0%	\$ 32,454	100.0%	\$ 9,554	29.4%	\$ 119,070	100.0%	\$ 92,375	100.0%	\$ 26,695	28.9%
Cost of sales	16,053	38.2	12,760	39.3	3,293	25.8	44,983	37.8	37,242	40.3	7,741	20.8
Gross profit	25,955	61.8	19,694	60.7	6,261	31.8	74,087	62.2	55,133	59.7	18,954	34.1
Operating expenses:												
Marketing and sales	5,409	12.9	4,442	13.7	967	21.8	16,222	13.6	13,440	14.5	2,782	20.7
Research and development	3,026	7.2	2,561	7.9	465	18.2	8,405	7.1	6,622	7.2	1,783	26.6
General and administrative	4,118	9.8	3,118	9.6	1,000	32.1	12,035	10.1	10,394	11.3	1,641	15.8
Goodwill impairment												
Other operating expenses	12,553	29.9	10,121	31.2	2,432	24.0	36,662	30.8	30,456	33.0	6,206	20.4
Income from operations	13,402	31.9	9,573	29.5	3,829	40.0	37,425	31.4	24,677	26.7	12,748	51.7
Other income (expense), net	31	0.1	314	1.0	(283)	*	149	0.1	(90)	(0.1)	239	23.9
Income before income taxes	13,433	32.0	9,887	30.5	3,546	35.9	37,574	31.5	24,587	26.6	12,987	52.8
Provision for income taxes	4,561	10.9	3,185	9.8	1,376	43.2	11,804	9.9	7,957	8.6	3,847	48.2
Net income	\$ 8,872	21.1%	\$ 6,702	20.7%	\$ 2,170	32.4%	\$ 25,770	21.6%	\$ 16,630	18.0%	\$ 9,140	55.0%

\*Percentage change not meaningful

Stock-based compensation expense included in the statements of operations data above is as follows:

(dollars in thousands)	Three Months Ended		Nine Months Ended	
	September 30, 2013	September 30, 2012	September 30, 2013	September 30, 2012
Stock options and grants	\$ 756	\$ 584	\$ 2,310	\$ 1,993
Employee stock purchase plan	103	158	285	369
<b>Total stock-based compensation expense</b>	<b>\$ 859</b>	<b>\$ 742</b>	<b>\$ 2,595</b>	<b>\$ 2,362</b>

Cost of revenue	\$ 89	\$ 103	\$ 233	\$ 248
Operating expenses:				
Marketing and sales	154	117	455	300
Research and development	201	142	555	346
General and administrative	415	380	1,352	1,468
Total stock-based compensation expense	\$ 859	\$ 742	\$ 2,595	\$ 2,362

*Comparison of Three Months Ended September 30, 2013 and 2012*

*Revenue*

Revenue by product line and the related changes for the three months ended September 30, 2013 and 2012 were as follows:

(dollars in thousands)	Three Months Ended September 30, 2013		2012		Change	
	\$	% of Total Revenue	\$	% of Total Revenue	\$	%
Revenue						
Protomold	\$ 29,534	70.3%	\$ 23,458	72.3%	\$ 6,076	25.9%
Firstcut	12,474	29.7	8,996	27.7	3,478	38.7
Total revenue	\$ 42,008	100.0%	\$ 32,454	100.0%	\$ 9,554	29.4%

**Table of Contents**

Revenue by geographic region, based on the billing location of the end customer, is summarized as follows:

(dollars in thousands)	Three Months Ended September 30,				Change	
	2013		2012		\$	%
	\$	% of Total Revenue	\$	% of Total Revenue		
Revenue						
United States	\$ 30,561	72.8%	\$ 24,807	76.4%	\$ 5,754	23.2%
International	11,447	27.2	7,647	23.6	3,800	49.7
Total revenue	\$ 42,008	100.0%	\$ 32,454	100.0%	\$ 9,554	29.4%

Our revenue increased \$9.6 million, or 29.4%, for the three months ended September 30, 2013 compared with the same period in 2012. This revenue growth was driven by a 23.2% increase in United States revenue, 49.7% increase in international revenue, 25.9% increase in Protomold revenue and 38.7% increase in Firstcut revenue, in each case for the three months ended September 30, 2013 compared with the same period in 2012.

Our revenue growth in the three months ended September 30, 2013 was the result of increased volume and spending of the product developers we served. During the three months ended September 30, 2013, we served approximately 7,300 unique product developers, an increase of 23% over the same period in 2012. Average revenue per product developer also increased 5% during the three months ended September 30, 2013 compared to the same period in 2012.

Our revenue increases were primarily driven by increases in sales personnel and marketing activities. Our sales personnel focus on gaining new customer accounts and expanding the depth and breadth into existing customer accounts. Our marketing personnel focus on trade show and marketing activities that have proven to result in the greatest number of customer leads to support sales activity. International revenue was negatively impacted by \$0.5 million in the three months ended September 30, 2013 compared to the same period in 2012 due to strengthening of the United States dollar relative to certain foreign currencies. The effect of pricing changes on revenue was immaterial for the three months ended September 30, 2013 compared to the same period in 2012.

*Cost of Revenue, Gross Profit and Gross Margin*

*Cost of Revenue.* Cost of revenue increased \$3.3 million, or 25.8%, for the three months ended September 30, 2013 compared to the same period in 2012, which was slower than the rate of revenue increase of 29.4% for the three months ended September 30, 2013 compared to the same period in 2012. The increase in cost of revenue was due to raw material and production cost increases of \$1.5 million to support increased sales volumes, equipment and facility-related cost increases of \$0.5 million and an increase in direct labor headcount resulting in personnel and related cost increases of \$1.3 million.

*Gross Profit and Gross Margin.* Gross profit increased to \$26.0 million, or 61.8% of revenues, for the three months ended September 30, 2013 from \$19.7 million, or 60.7% of revenues, for the three months ended September 30, 2012 due to increases in revenue offset by the cost of revenue as discussed above. Gross margin increased primarily as a result of efficiencies gained through higher equipment utilization and continually refined manufacturing processes as well as a growth rate in order volume that exceeded capacity expansion through capital equipment acquisition.

*Operating Expenses, Other Income (Expense), net and Provision for Income Taxes*

*Marketing and Sales.* Marketing and sales expense increased \$1.0 million, or 21.8%, for the three months ended September 30, 2013 compared to the same period in 2012 due primarily to an increase in headcount resulting in personnel and related cost increases of \$0.9 million and marketing program cost increases of \$0.1 million. The increase in marketing program costs is the result of our focus and concentration on funding those programs which have proven to be the most effective in growing our business. Marketing and sales expense as a percentage of revenue decreased to 12.9% for the three months ended September 30, 2013 from 13.7% during the same period in 2012, primarily due to the fixed nature of certain marketing and sales costs as well as focus on effective marketing spending as previously discussed.

*Research and Development.* Our research and development expense increased \$0.5 million, or 18.2%, for the three months ended September 30, 2013 compared to the same period in 2012 due to an increase in headcount resulting in personnel and related cost increases of \$0.5 million and operating cost increases of \$0.2 million, which were partially offset by a decrease in professional services of \$0.2 million for outside development services.



**Table of Contents**

*General and Administrative.* Our general and administrative expense increased \$1.0 million, or 32.1%, for the three months ended September 30, 2013 compared to the same period in 2012 due to an increase in headcount resulting in personnel and related cost increases of \$0.2 million, administrative cost increases of \$0.5 million and professional service cost increases of \$0.3 million. The increase in professional service costs is attributable to our becoming a public company during the first quarter of 2012.

*Other Income (Expense), net.* Other income, net decreased \$0.3 million for the three months ended September 30, 2013 compared to the same period in 2012 due to changes in foreign currency rates.

*Provision for Income Taxes.* Our effective tax rate of 34.0% for the three months ended September 30, 2013 increased by 1.8% when compared to our effective tax rate of 32.2% for the same period in 2012. The increase in effective tax rate is due to the annual provision to return reconciliation as well as changes in components of income and the magnitude to which we can take certain tax deductions. As a result of the change in effective tax rate as well as increased income attributable to the fluctuations described above, our income tax provision increased by \$1.4 million to \$4.6 million for the three months ended September 30, 2013 compared to our income tax provision of \$3.2 million for the three months ended September 30, 2012.

**Comparison of Nine Months Ended September 30, 2013 and 2012***Revenue*

Revenue by product line and the related changes for the nine months ended September 30, 2013 and 2012 were as follows:

(dollars in thousands)	Nine Months Ended September 30, 2013		2012		Change	
	\$	% of Total Revenue	\$	% of Total Revenue	\$	%
Revenue						
Protomold	\$ 84,338	70.8%	\$ 66,697	72.2%	\$ 17,641	26.4%
Firstcut	34,732	29.2	25,678	27.8	9,054	35.3
Total revenue	\$ 119,070	100.0%	\$ 92,375	100.0%	\$ 26,695	28.9%

Revenue by geographic region, based on the billing location of the end customer, is summarized as follows:

(dollars in thousands)	Nine Months Ended September 30, 2013		2012		Change	
	\$	% of Total Revenue	\$	% of Total Revenue	\$	%
Revenue						
United States	\$ 88,816	74.6%	\$ 69,887	75.7%	\$ 18,929	27.1%
International	30,254	25.4	22,488	24.3	7,766	34.5

Edgar Filing: Proto Labs Inc - Form 10-Q

Total revenue	\$ 119,070	100.0%	\$ 92,375	100.0%	\$ 26,695	28.9%
---------------	------------	--------	-----------	--------	-----------	-------

Our revenue increased \$26.7 million, or 28.9%, for the nine months ended September 30, 2013 compared with the same period in 2012. This revenue growth was driven by a 27.1% increase in United States revenue, 34.5% increase in international revenue, 26.4% increase in Protomold revenue and 35.3% increase in Firstcut revenue, in each case for the nine months ended September 30, 2013 compared with the same period in 2012.

Our revenue growth in the nine months ended September 30, 2013 was the result of increased volume and spending of the product developers we served. During the nine months ended September 30, 2013, we served approximately 13,400 unique product developers, an increase of 21% over the same period in 2012. Average revenue per product developer also increased 7% during the nine months ended September 30, 2013 compared to the same period in 2012.

---

**Table of Contents**

Our revenue increases were primarily driven by increases in sales personnel and marketing activities. Our sales personnel focus on gaining new customer accounts and expanding the depth and breadth into existing customer accounts. Our marketing personnel focus on trade show and marketing activities that have proven to result in the greatest number of customer leads to support sales activity. International revenue was negatively impacted by \$1.4 million in the nine months ended September 30, 2013 compared to the same period in 2012 due to strengthening of the United States dollar relative to certain foreign currencies. The effect of pricing changes on revenue was immaterial for the nine months ended September 30, 2013 compared to the same period in 2012.

*Cost of Revenue, Gross Profit and Gross Margin*

*Cost of Revenue.* Cost of revenue increased \$7.7 million, or 20.8%, for the nine months ended September 30, 2013 compared to the same period in 2012, which was slower than the rate of revenue increase of 28.9% for the nine months ended September 30, 2013 compared to the same period in 2012. The increase in cost of revenue was due to raw material and production cost increases of \$3.2 million to support increased sales volumes, equipment and facility-related cost increases of \$1.5 million and an increase in direct labor headcount resulting in personnel and related cost increases of \$3.0 million.

*Gross Profit and Gross Margin.* Gross profit increased to \$74.1 million, or 62.2% of revenues, for the nine months ended September 30, 2013 from \$55.1 million, or 59.7% of revenues, for the nine months ended September 30, 2012 due to increases in revenue offset by the cost of revenue as discussed above. Gross margin increased primarily as a result of efficiencies gained through higher equipment utilization and continually refined manufacturing processes as well as a growth rate in order volume that exceeded capacity expansion through capital equipment acquisition.

*Operating Expenses, Other Income (Expense), net and Provision for Income Taxes*

*Marketing and Sales.* Marketing and sales expense increased \$2.8 million, or 20.7%, for the nine months ended September 30, 2013 compared to the same period in 2012 due primarily to an increase in headcount resulting in personnel and related cost increases of \$2.6 million and marketing program cost increases of \$0.2 million. The increase in marketing program costs is the result of our focus and concentration on funding those programs which have proven to be the most effective in growing our business. Marketing and sales expense as a percentage of revenue decreased to 13.6% for the nine months ended September 30, 2013 from 14.5% during the same period in 2012, primarily due to the fixed nature of certain marketing and sales costs as well as focus on effective marketing spending as previously discussed.

*Research and Development.* Our research and development expense increased \$1.8 million, or 26.9%, for the nine months ended September 30, 2013 compared to the same period in 2012 due to an increase in headcount resulting in personnel and related cost increases of \$1.3 million, operating cost increases of \$0.4 million and professional services of \$0.1 million for outside development services.

*General and Administrative.* Our general and administrative expense increased \$1.6 million, or 15.8%, for the nine months ended September 30, 2013 compared to the same period in 2012 due to an increase in headcount resulting in personnel and related cost increases of \$0.4 million, professional service cost increases of \$0.6 million and administrative cost increases of \$0.7 million, which were partially offset by a decrease in stock-based compensation costs of \$0.1 million. The increase in professional service costs is attributable to our becoming a public company during the first quarter of 2012.

*Other Income (Expense), net.* Other income, net increased \$0.2 million for the nine months ended September 30, 2013 compared to the same period in 2012 due to changes in foreign currency rates.

*Provision for Income Taxes.* Our income tax provision increased by \$3.8 million to \$11.8 million while our effective tax rate decreased by 1.0% to 31.4% for the nine months ended September 30, 2013 compared to income tax provision of \$8.0 million and effective tax rate of 32.4% for the nine months ended September 30, 2012. On January 2, 2013, the American Taxpayer Relief Act of 2012 (the Act) was signed into law, extending the research and development credit for years 2012 and 2013. As the Act was enacted during 2013, the federal portion of the 2012 research and development credit was recognized in the first quarter of 2013. We recorded a tax benefit of \$0.3 million for the 2012 federal research credit, which translated to an effective income tax rate reduction of 1.0% for the nine months ended September 30, 2013.

**Table of Contents*****Liquidity and Capital Resources******Cash Flows***

The following table summarizes our cash flows for the nine months ended September 30, 2013 and 2012:

(dollars in thousands)	<b>Nine Months Ended September 30,</b>	
	<b>2013</b>	<b>2012</b>
Net cash provided by operating activities	\$ 34,900	\$ 19,434
Net cash used in investing activities	(44,970)	(65,713)
Net cash provided by financing activities	12,622	74,604
Effect of exchange rates on cash and cash equivalents	71	(170)
<b>Net increase in cash and cash equivalents</b>	<b>\$ 2,623</b>	<b>\$ 28,155</b>

***Sources of Liquidity***

Historically we have financed our operations and capital expenditures through operations, lease financing and the use of bank loans. In February 2012, we completed the IPO of our common stock, which provided us with \$71.5 million of cash, net of underwriting discounts and commissions and offering expenses payable by us. We had cash and cash equivalents of \$39.4 million as of September 30, 2013, an increase of \$2.6 million from December 31, 2012. The increase in our cash was primarily due to cash provided through operations partially offset by investment activity described in Note 5 to the consolidated financial statements.

***Cash Flows from Operating Activities***

Cash provided by operating activities was \$34.9 million for the nine months ended September 30, 2013. We had net income of \$25.8 million, which included non-cash charges consisting of \$5.5 million in depreciation, \$2.6 million in stock-based compensation, \$1.0 million in amortization of held-to-maturity securities and \$0.1 million in loss on the disposal of property and equipment, offset by \$8.2 million of excess tax benefit on stock-based compensation and \$0.1 million of deferred taxes. Other sources of cash in operating activities totaled \$8.2 million, which included an increase in income taxes payable of \$6.1 million, increase in prepaid expenses and other of \$1.5 million, increase in accounts payable of \$1.6 million and increase in accrued liabilities and other of \$1.6 million, which were partially offset by an increase in accounts receivable of \$2.2 million and increase in inventories of \$0.4 million. These operating cash increases in accounts receivable, accounts payable, inventories and other reflect increases in revenue and the growth of our business.

Cash provided by operating activities was \$19.4 million for the nine months ended September 30, 2012. We had net income of \$16.6 million, which included non-cash charges consisting of \$4.4 million in depreciation and \$2.4 million in stock-based compensation and \$0.1 million in amortization of held-to-maturity securities, offset by \$2.6 million of excess tax benefit on stock-based compensation. Other uses of cash in operating activities totaled \$1.5 million, which included an increase in accounts receivable of \$3.8 million, increase in inventory of \$0.5 million, increase in prepaid and other expenses of \$0.3 million and a decrease in accounts payable of \$0.3 million, which were partially offset by an increase in income taxes payable of \$2.4 million and increase in accrued and other liabilities of \$1.0 million. The increase in accounts receivable reflects increases in revenue.

*Cash Flows from Investing Activities*

Cash used in investing activities was \$45.0 million for the nine months ended September 30, 2013, consisting of \$13.0 million for the purchase of property and equipment and \$82.7 million for the purchase of marketable securities, which were partially offset by \$50.7 million in proceeds from the maturities and call redemptions of marketable securities.

Cash used in investing activities was \$65.7 million for the nine months ended September 30, 2012, consisting of \$14.4 million for the purchase of property and equipment and \$61.6 million for the purchase of marketable securities, which were partially offset by \$10.3 million in proceeds from the sale and call redemption of marketable securities.

*Cash Flows from Financing Activities*

Cash provided by financing activities was \$12.6 million for the nine months ended September 30, 2013, consisting of excess tax benefit on stock-based compensation of \$8.2 million and \$4.6 million in proceeds from exercises of stock options, partially offset by \$0.2 million for payments of debt.

## **Table of Contents**

Cash provided by financing activities was \$74.6 million for the nine months ended September 30, 2012, consisting of \$71.5 million from the IPO of our common stock, excess tax benefit on stock-based compensation of \$2.6 million and \$0.8 million in proceeds from exercises of stock options and warrants, partially offset by \$0.3 million for payments of debt.

### **Off-Balance Sheet Arrangements**

Since our inception, we have not engaged in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities.

### **Critical Accounting Policies and Use of Estimates**

We have adopted various accounting policies to prepare the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). Our most significant accounting policies are discussed herein.

The preparation of the consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying Notes. Our estimates and assumptions, including those related to revenue recognition, the allowance for doubtful accounts, inventory valuation, stock-based compensation and income taxes, are updated as appropriate, which in most cases is quarterly.

We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. In many cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Management has discussed the development, selection and disclosure of these estimates with the audit committee of our board of directors. Our actual results may differ significantly from these estimates under different assumptions or conditions.

We believe the following critical accounting policies affect our more significant judgments used in the preparation of our consolidated financial statements.

#### *Revenue Recognition*

We recognize revenue in accordance with ASC 605, *Revenue Recognition* (ASC 605), which states that revenue is realized or realizable and earned when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price to the buyer is fixed or determinable, and (4) collectability is reasonably assured.

Revenue is generally recognized upon transfer of title and risk of loss, which for us is upon shipment of parts.

#### *Allowance for Doubtful Accounts*

We carry our accounts receivable at their invoiced amount less an allowance for doubtful accounts. On a periodic basis, we evaluate our accounts receivable and establish an allowance for doubtful accounts based on the history of write-offs and collections. A receivable is considered past due if payment has not been received within the period agreed upon in the invoice. Accounts receivable are written off after all collection efforts have been exhausted. To date, we have not incurred any write-offs of accounts receivable significantly different than the amounts reserved. We

believe appropriate reserves have been established, but they may not be indicative of future write-offs. Our allowance for doubtful accounts was \$0.2 million as of each of September 30, 2013 and December 31, 2012. Our allowance for doubtful accounts has decreased as a percentage of accounts receivable due to improvements in account aging driven by stronger credit policies.

We also record a provision for estimated product returns and allowances in the period in which the related revenue is recorded. This provision against current gross revenue is based principally on historical rates of sales returns.

*Inventory Valuation and Inventory Reserves*

Inventory consists primarily of raw materials, which are recorded at the lower of cost or market, using the average-cost method, which approximates first-in, first-out, or FIFO, cost. We periodically review our inventory for slow-moving, damaged and discontinued items and provide reserves to reduce such items identified to their recoverable amounts. Our inventory allowance for obsolescence was \$0.1 million as of each of September 30, 2013 and December 31, 2012.



## **Table of Contents**

### *Stock-Based Compensation*

We determine our stock-based compensation in accordance with ASC 718, *Compensation Stock Compensation* (ASC 718), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee directors based on the grant date fair value of the award.

Determining the appropriate fair value model and calculating the fair value of stock option grants requires the input of highly subjective assumptions. We use the Black-Scholes option pricing model to value our stock option awards. Stock-based compensation expense is significant to our consolidated financial statements and is calculated using our best estimates, which involve inherent uncertainties and the application of management's judgment. Significant estimates include our expected term, stock price volatility and forfeiture rates. If different estimates and assumptions had been used, our common stock valuations could be significantly different and related stock-based compensation expense may be materially impacted.

The Black-Scholes option pricing model requires inputs such as the risk-free interest rate, expected term, expected volatility and expected dividend yield. We base the risk-free interest rate that we use in the Black-Scholes option pricing model on zero coupon U.S. Treasury instruments with maturities similar to the expected term of the award being valued. The expected term represents the weighted-average period that our stock options are expected to be outstanding. The expected term is based on the observed and expected time to post-vesting exercise of options by employees and non-employee directors and considers the impact of post-vesting award forfeitures. Because we operated as a private company with a limited market for our stock from inception to the completion of our IPO in February 2012, we estimate the volatility of our common stock based on volatility of a peer group of comparable publicly traded companies for which historical information is available. We have never paid and do not anticipate paying any cash dividends in the foreseeable future and, therefore, we use an expected dividend yield of zero in the option pricing model. In order to properly attribute compensation expense, we are required to estimate pre-vesting forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. If our actual forfeiture rate is materially different from our estimate, stock-based compensation expense could be significantly different from what has been recorded.

We allocate stock-based compensation expense on a straight-line basis over the requisite service period.

### *Income Taxes*

We account for income taxes in accordance with ASC 740, *Income Taxes* (ASC 740). Under this method, we determine tax assets and liabilities based upon the differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. The tax consequences of most events recognized in the current year's financial statements are included in determining income taxes currently payable. However, because tax laws and financial accounting standards differ in their recognition and measurement of assets, liabilities and equity, revenues, expenses, gains and losses, differences arise between the amount of taxable income and pretax financial income for a year and between the tax basis of assets or liabilities and their reported amounts in the financial statements. Because we assume that the reported amounts of assets and liabilities will be recovered and settled, respectively, a difference between the tax basis of an asset or liability and its reported amount in the balance sheet will result in a taxable or a deductible amount in some future years when the related liabilities are settled or the reported amounts of the assets are recovered, giving rise to a deferred tax asset or liability.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements by defining a criterion that an individual tax position must meet for any part of the benefit of that position to be recognized in an enterprise's financial statements. Additionally, ASC 740 provides guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

### **Recent Accounting Pronouncements**

For information on recent accounting pronouncements, see Note 2 to the consolidated financial statements appearing in Part I, Item 1 in this Quarterly Report on Form 10-Q.

**Table of Contents**

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

**Foreign Currency Risk**

As a result of our foreign operations, we have revenue and expenses, assets and liabilities that are denominated in foreign currencies. A number of our employees are located in Europe and Japan. Therefore, a portion of our payrolls and operating expenses are paid and incurred in the British Pound, Euro and Yen. Our operating results and cash flows are adversely impacted when the U.S. dollar depreciates relative to other foreign currencies. We have not used any forward contracts or currency borrowings to hedge our exposure to foreign currency exchange risk. Foreign currency risk can be quantified by estimating the change in cash flows resulting from a hypothetical 10% adverse change in foreign exchange rates. We believe such a change would not have a material impact on our results of operations.

**Table of Contents**

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (Exchange Act)) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures are effective and provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported accurately and within the time frames specified in the SEC's rules and forms and accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

**Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents****PART II. OTHER INFORMATION****Item 1. Legal Proceedings**

From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of these financial statements, we do not believe we are party to any litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business.

**Item 1A. Risk Factors**

There have been no material changes from the risk factors we previously disclosed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2012.

**Item 6. Exhibits**

The following documents are filed as part of this report:

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
3.1 <sup>(1)</sup>	Third Amended and Restated Articles of Incorporation of Proto Labs, Inc.
3.2 <sup>(2)</sup>	Amended and Restated By-Laws of Proto Labs, Inc.
31.1	Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
31.2	Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
32.1*	Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act
101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Extension Schema Document
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase Document

(1) Previously filed as Exhibit 3.2 to the Company's Registration Statement on Form S-1/A (File No. 333-175745), filed with the Commission on February 13, 2012, and incorporated by reference herein.

(2) Previously filed as Exhibit 3.4 to the Company's Registration Statement on Form S-1/A (File No. 333-175745), filed with the Commission on February 13, 2012, and incorporated by reference herein.

\*

## Edgar Filing: Proto Labs Inc - Form 10-Q

The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

\*\* Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability under these sections.

Table of Contents

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Proto Labs, Inc.

/s/ Bradley A. Cleveland  
Bradley A. Cleveland  
President and Chief Executive Officer

(Principal Executive Officer)

Date: November 5, 2013

/s/ John R. Judd  
John R. Judd  
Chief Financial Officer

(Principal Financial Officer)

Date: November 5, 2013